Dipeptidyl peptidase-4 (DPP-4) inhibitors have exceptional safety and efficacy characteristics and are commonly employed to treat patients suffering from chronic kidney disease and diabetes mellitus as a comorbidity. Here, DPP4 is linked to chronic kidney disease.